Kidney Week 2018: Exhibitor Spotlight Schedule

Thursday, October 25 – Saturday, October 27

Exhibit Hall Floor

Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in two theaters on the exhibit hall floor. Seating is limited and available on a first come, first served basis. Exhibitor Spotlights are not CE (continuing education) activities.

All presentations include breakfast or lunch.

Thursday, October 25

10:00 a.m. – 11:00 a.m.
Diagnosing and Managing Fabry Disease
Presented by Sanofi Genzyme

11:00 a.m. – 12:00 p.m.
A Silent Threat: Hyperkalemia in Patients with Diabetes, Heart Failure and CKD
Presented by Relypsa Inc., A Vifor Pharma Group Company

12:00 p.m. – 1:00 p.m.
The Role of Parsabiv™ (etelcalcetide) in the Treatment of Secondary Hyperparathyroidism (HPT) in Adult Patients on Hemodialysis
Presented by Amgen

1:00 p.m. – 2:00 p.m.
Thrombotic Microangiopathy Team Approach
Presented by Alexion Pharmaceuticals, Inc.

Friday, October 26

10:00 a.m. – 11:00 a.m.
2008T BlueStar Hemodialysis Machine – Advancing Dialysis Care
Presented by Fresenius Medical Care

11:00 a.m. – 12:00 p.m.
Survival After End Stage Renal Failure: Preventing Cardiac Disease in ESRD Patients
Presented by NxStage Medical, Inc.

12:00 p.m. – 1:00 p.m.
Rituxan (Rituximab) for the Treatment of Granulomatosis with Polyangitis (GPA) and MPA
Presented by Genentech

1:00 p.m. – 2:00 p.m.
Long-Term Results of Treatment Across a Broad Range of Patients with Type 2 Diabetes
Presented by Janssen Pharmaceuticals, Inc.

Saturday, October 27

10:00 a.m. – 11:00 a.m.
Iron Deficiency Anemia: Moving from Clinical Trials to Clinical Practice in Nephrology
Presented by Daiichi-Sankyo, Inc.

11:00 a.m. – 12:00 p.m.
Science to Solution: Expanded Hemodialysis
Presented by Baxter Healthcare Corporation

12:00 p.m. – 1:00 p.m.
Treating Hyperuricemia in Uncontrolled Gout Patients with Chronic Kidney Disease
Presented by Horizon Pharma

1:00 p.m. – 2:00 p.m.
Is it More Than a Kidney Stone: Identifying and Managing Patients with a Rare Kidney Disease, Primary Hyperoxaluria Type 1
Presented by Alnylam Pharmaceuticals

*Additional information included by clicking on title if provided by supporter.